your market intelligence analyst
Search Results
Edit Save
97 results
Immuno-Oncology News 11/13/2019 11:14
CytomX Therapeutics has initiated a Phase 2 clinical trial to test a combination of its probody CX-072 — a type of engineered antibody — with Yervoy (ipilimumab) for treating people with relapsed or refractory melanoma. The investigational probody CX-072 and Yervoy, developed by Bristol-Myers Squibb, are two immune checkpoint inhibitors designed to boost the body’s […]. .
Immuno-Oncology News 11/08/2019 12:48
The investigational therapy MDNA55 increases survival in people with recurrent glioblastoma, a type of brain cancer — especially in those who produce high levels of ILR4, a marker of aggressive disease, updated results of a clinical trial show. Fahar Merchant, president and CEO of Medicenna Therapeutics, MDNA55’s developer, presented the findings at the inaugural Targeting Innate […]. .
Immuno-Oncology News 11/06/2019 10:26
First-line treatment with a combination of Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) added to a shorter course of chemotherapy significantly extends the survival of people with advanced non-small cell lung cancer (NSCLC), compared to standard chemotherapy alone, early Phase 3 trial results show.
Immuno-Oncology News 11/04/2019 11:53
A combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) extends overall survival and the time lived without disease progression in people with newly-diagnosed, inoperable hepatocellular carcinoma (HCC), the most common type of liver cancer, compared to standard-of-care treatment with Nexavar (sorafenib), results from the IMbrave150 Phase 3 trial show.
Immuno-Oncology News 10/22/2019 12:39
AstraZeneca‘s Imfinzi (durvalumab) decreases the spread of cancer to other parts of the body, explaining the enhanced survival in patients with stage 3 inoperable non-small-cell lung cancer (NSCLC), according to a new analysis of Phase 3 data. This analysis of survival data was gathered from the Phase 3 PACIFIC trial (NCT02125461) where treatment with Imfinzi — […]. .
Immuno-Oncology News 10/16/2019 10:59
Bristol-Myers Squibb‘s Opdivo (nivolumab) is superior to chemotherapy for treating patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) that cannot be removed surgically, and who are resistant or intolerant to combination therapy with fluoropyrimidine and platinum-based treatments, the ATTRACTION-3 clinical trial shows.
Immuno-Oncology News 09/27/2019 08:57
The U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to Mateon‘s OT101 as a therapy for diffuse intrinsic pontine glioma (DIPG), a difficult-to-treat brain tumor that affects children. The designation is designed to accelerate the development of therapies that can improve the management of serious or life-threatening conditions affecting less than 200,000 […]. .
Immuno-Oncology News 09/24/2019 10:45
A combination of ilixadencel plus Sutent (sunitinib) is showing promising efficacy in patients with kidney cancer that has spread to other organs, according to topline data from a Phase 2 trial. Ilixadencel, Immunicum‘s lead candidate for the treatment of different types of solid tumors, is a cancer vaccine based on the use of dendritic cells […]. .
Immuno-Oncology News 09/20/2019 09:52
Magrolimab, an experimental antibody developed by Forty Seven, was granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The designation is given to therapies that show potential to treat serious health conditions, and is intended to accelerate their development and approval […]. .
Immuno-Oncology News 09/13/2019 11:01
Immunotherapies have shown little efficacy in brain cancers due to their inability to cross the blood-brain barrier. Now, however, researchers have developed a new nanotechnology approach that allowed immune checkpoint inhibitors to enter the brains of mice with glioblastoma. The approach increased the amount of immune cells reaching the tumor and improved the survival of […]. .
Immuno-Oncology News 09/11/2019 08:42
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BXCL701, one of BioXcel Therapeutics’ lead immunotherapies for the treatment of acute myeloid leukemia (AML). Orphan drug status is given to investigative treatments for rare diseases, defined in the U.S. as disorders that affect fewer than 200,000 people. The designation comes with […]. .
Immuno-Oncology News 09/04/2019 10:48
Cellectar Biosciences announced that a second and higher dose of its investigational radiotherapeutic compound, CLR 131, was cleared for use in its ongoing CLOVER-2 study in children with advanced solid cancers, lymphomas, and brain tumors. The independent committee overseeing the trial recommended moving to a higher dose after the first dose tested was found safe […]. .

Agribusiness Economics

Business Issues

Companies - Public

Companies - Venture Funded

Agricultural Equipment

Chemicals - Agricultural

Chemicals - Industrial

Commodity Prices

Farm Financial Services

Farming, Forestry, Fisheries

Financial Results

Food and Human Nutrition

Global Markets

Global Risk Factors

Government Agencies

Information Technologies

Legal and Regulatory

Political Entities

Products - Animal

Products - Forest

Products - Plant


Strategic Scenarios




On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications